New lupus kidney drugs enter first human safety tests
NCT ID NCT06975787
Summary
This early-stage study is testing two new antibody drugs for people with lupus nephritis, a serious kidney complication of lupus. The main goal is to check how safe and tolerable these experimental treatments are when given for a short period. The study will enroll 90 participants who have not responded well to previous treatments or whose disease has returned.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUPUS NEPHRITIS (LN) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Changhua Christian Hospital
RECRUITINGChanghua, 500, Taiwan
-
Mayo Clinic
RECRUITINGRochester, Minnesota, 55905, United States
-
Samsung Medical Center
RECRUITINGSeoul, 06351, South Korea
-
Seoul National University Hospital
RECRUITINGSeoul, 03080, South Korea
-
Taipei Veterans General Hospital
RECRUITINGTaipei, 112, Taiwan
-
University Medical Center of the Johannes Gutenberg-University Mainz
RECRUITINGMainz, 55131, Germany
Conditions
Explore the condition pages connected to this study.